Description
Product details
VILDIABATE PIO Vildagliptin 50 mg & Pioglitazone Hydrochloride 15 mg Introduction Type 2 diabetes management often necessitates a multidimensional treatment strategy to effectively control blood glucose levels and reduce the risk of complications. VILDIABATE PIO combines two potent diabetes medications: Vildagliptin (50 mg) and Pioglitazone Hydrochloride (15 mg). This combination leverages the complementary mechanisms of both drugs to offer an enhanced therapeutic effect. This article discusses the benefits, mode of action, and clinical utility of VILDIABATE PIO in the management of Type 2 diabetes. Understanding the Components of VILDIABATE PIO Vildagliptin (50 mg) Vildagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that enhances the body's natural ability to regulate blood sugar levels. It works by inhibiting the enzyme DPP-4, which is responsible for breaking down incretin hormones such as GLP-1 and GIP. These hormones play a crucial role in the regulation of glucose metabolism by increasing insulin release and decreasing glucagon secretion in response to meals, thereby aiding in the reduction of postprandial blood glucose levels. Pioglitazone Hydrochloride (15 mg) Pioglitazone is a type of medication known as a thiazolidinedione, which works primarily by increasing insulin sensitivity in peripheral tissues, such as muscle and fat. It also mildly suppresses hepatic gluconeogenesis. The overall effect is a reduction in insulin resistance, which is a core problem in Type 2 diabetes, making pioglitazone particularly effective for improving glucose control in patients who are insulin resistant. Synergistic Benefits for Diabetes Management Enhanced Glycemic Control By combining Vildagliptin and Pioglitazone, VILDIABATE PIO addresses two major aspects of diabetes management: postprandial glucose spikes and insulin resistance. Vildagliptin improves the incretin system, enhancing pancreatic response to glucose intake, while Pioglitazone works to improve the effectiveness of endogenous insulin. This dual action is effective in reducing both fasting and postprandial blood glucose levels, offering comprehensive glycemic management. Reduced Risk of Hypoglycemia VILDIABATE PIO provides a significant advantage in terms of safety. The mechanism of action of both Vildagliptin and Pioglitazone does not inherently cause hypoglycemia as they do not directly stimulate excessive insulin secretion. This makes the combination safer compared to other therapies that might induce hypoglycemia, especially beneficial for elderly patients or those with renal impairment. Benefits Beyond Glucose Control In addition to controlling blood sugar, Pioglitazone has been shown to have favorable effects on lipid profiles, potentially lowering triglycerides and increasing HDL cholesterol. This cardiovascular risk reduction is an important aspect of diabetes care, given the high risk of heart disease associated with diabetes. For further information: EMAIL: info@sterispharma.com / contact@sterispharma.com CALL/WHATSAPP:: 7877551268, 8209542042, 8955945010, 6377716668 https://www.sterisonline.com/product/vildiabate-pio-134257
